We used global gene expression profiles from human B-cell cell lines to generate gene expression signatures for prediction of response to the drugs cyclophosphamide, doxorubicin or vincristine. The signatures were validated in two publicly available clinical cohorts.
Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.
Disease, Cell line
View SamplesWe studied 498 de-novo adult DLBCL cases, which had been diagnosed between January 2002 and October 2009, as part of the International DLBCL Rituximab-CHOP Consortium Program Study
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
No sample metadata fields
View SamplesThis SuperSeries is composed of the SubSeries listed below:
Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.
Specimen part
View SamplesPurpose
Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.
Specimen part
View SamplesPurpose
Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.
Specimen part
View Samples